Tag Archive > Licensed Products

Eisai Expands in Israeli Market With Approval of Halaven

Hatfield, England (ots/PRNewswire) – Metastatic breast cancer treatment Halaven(R) (eribulin) provides a statistically significant overall survival benefit for women with the disease Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has recently received registration approval from the […]

Continue reading

, , , , , , , , , , , , , , , , , , ,

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

Woburn, Massachusetts (ots/PRNewswire) – ArQule, Inc. and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, with an option for a fourth, in the field of oncology, […]

Continue reading

, , , , , , , , , , , , , , , , , , ,